HEK293-CD20 Cells
2 622,00 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. HEK293-CD20 cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human CD20 (MS4A1), a non-glycosylated transmembrane phosphoprotein primarily expressed on B lymphocytes. CD20 is involved in regulation of B-cell activation, proliferation, differentiation, and calcium signaling, and serves as one of the most extensively validated therapeutic targets in hematologic malignancies and autoimmune diseases. Stable HEK293-CD20 models provide controlled and reproducible surface expression of the antigen, enabling detailed characterization of CD20-targeted therapeutics and immune-mediated mechanisms. HEK293-CD20 cells are widely used in immuno-oncology and biologics development for evaluation of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and engineered immune cell therapies targeting CD20. These cells support quantitative analysis of antibody binding affinity, epitope specificity, receptor occupancy, internalization dynamics, and Fc-mediated immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). They are also commonly applied in flow cytometry assay development, potency testing, reporter bioassays, and high-throughput therapeutic screening workflows. Because HEK293 cells support efficient recombinant protein expression and robust cell growth, they provide a reliable and scalable platform for standardized assay generation and target validation studies. |
|---|---|
| Organisme | Human |
| Tissu | Fetal Kidney |
| Maladie | Transformed/immortalized; non-tumorigenic (HEK293 background) |
| Applications | CD20-targeted antibody and bispecific antibody development; CAR-T cell therapy; ADCC/CDC assays; flow cytometry; biologics potency testing; B-cell antigen research |
Caractéristiques
| Âge | Fetus |
|---|---|
| Genre | Female |
| Morphologie | Epithelial-like |
| Type de cellule | Epithelial cells |
| Propriétés de croissance | Monolayer, adherent |
Données réglementaires
| Référence | HEK293-CD20 (Cytion catalog number 305987) |
|---|---|
| Niveau de biosécurité | 1 |
| NCBI_Numéro d'identification fiscale | 9606 |
| Cellosaurus - Numéro d'enregistrement | CVCL_A8V4 |
| Statut OGM | GMO-S1: This HEK293 cell line contains a CD20 (MS4A1) expression construct for therapeutic antibody and immune effector function studies. This classification applies only within Germany and may differ elsewhere. |
Données biomoléculaires
| Récepteurs exprimés | CD20 |
|---|
Manipulation
| Milieu de culture | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suppléments | Supplement the medium with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. |
| Réactif de dissociation | Trypsin-EDTA |
| Temps de doublement | approx. 24-36 hours |
| Repiquage | For routine adherent cell culture: Aspirate the old culture medium from the adherent cells, and wash them with PBS to remove any remaining medium. After aspirating the PBS, add the appropriate volume of Trypsin/EDTA solution based on the culture vessel size (e.g., 1 ml for a T25 flask, 3 ml for a T75 flask) and incubate at room temperature or 37°C until the cells detach (5-10 minutes). Monitor detachment under a microscope, and gently tap the vessel if necessary to release the cells. Once detached, add complete medium to inactivate the Trypsin/EDTA, gently resuspend the cells, and transfer an aliquot of the cell suspension into a new culture vessel containing fresh medium. Place the vessel in an incubator set to 37°C with 5% CO2, and change the medium every 2-3 days. |
| Rapport de fractionnement | 1 to 5 |
| Densité de semis | 2 to 4 x 104 cells/cm2 |
| Renouvellement des fluides | 2 to 3 times per week |
| Rétablissement après le dégel | After thawing, split the cells at a ratio of 1:2 to 1:3 in T25 flasks and allow the cells to recover from the freezing process and to adhere (for adherent cultures) for at least 24 hours. |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
| Stérilité | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|